Group items tagged

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Mesothelioma Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Leukemia/Lymphoma/Myeloma Cells for your research.

Creative Bioarray maintains various human and animal tumor cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray consistently attains the highest standards and uses the most reliable procedures to verify every cell line.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Melanoma Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Uterine/Cervix Tumor Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Thyroid Tumor Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Mouse Tumor Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Endocrine Cells for your research.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Gastrointestinal Cells for your research. Call 1-631-626-9181 or Email us at contact@creative-bioarray.com to know more.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Gallbladder Cells for your research. Call 1-631-626-9181 or Email us at contact@creative-bioarray.com to know more.

Creative Bioarray provides various human and animal cell lines that are invaluable for medical, scientific and pharmaceutical institutions. Creative Bioarray offers Embryonic Stem Cells for your research.

February 14, 2009 - (BRONX, NY) - Scientists at Albert Einstein College of Medicine of Yeshiva University have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that selectively target and destroy microbial and HIV-infected cells. The experimental treatment - called radioimmunotherapy, or RIT - holds promise for treating various infectious diseases, including HIV and cancers caused by viruses. The research was presented today at the annual meeting of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and the publishers of the journal Science.

"The clinical potential for a liver-protective supplement in cancer care is significant, as I've observed in many years of integrative medical practice," writes Dr. Keith Block, ICT editor. "Several chemotherapy drugs, as well as many of the other drugs cancer patients take, have extremely problematic liver toxicities. With this exclusive edition, the scientific community will have a resource to guide and inspire further research on this very interesting herbal medicine."

Second Expert Report\n\nFood, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective\n\nIt began in 2001 with AICR and its international affiliate, WCRF-UK committing themselves to systematically review and analyze the total body of scientific evidence on the relationship of diet, physical activity and weight management to cancer risk. After a rigorous five-year process, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective does just that.

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res

Determining the best way of treating cancer remains highly controversial, even among mainstream oncologists. What may surprise the reader is the large number of documented therapies that have been overlooked by establishment medicine. The fundamental objective of this book is to encourage the expedient transfer of published scientific findings from the research bench to the clinical setting where the patient may benefit. This is the concept of translational medicine, which means translating knowledge from the laboratory side of medicine to the front lines of patient care. Physicians who practice translational medicine react uniquely when informed about a novel therapy. Their curiosity first motivates them to evaluate the new approach in order to reaffirm safety and efficacy in the context of treatment that is appropriate to the patient's condition. The dedicated translational physician uses novel therapeutics based on:

Beta glucan is a scientifically proven biological defense modifier (BDM) that nutritionally potentiates and modulates the immune response. As a supplement, after swallowing orally, Beta glucan is ingested primarily through macrophage and dendritic immune cells, to nutritionally and safely yield, through immune response potentiation and modulation, in many instances various therapeutic healing effects generated by the immune cells.  For many years Glucans have been investigated (History) for these immune enhancing properties, particularly their ability to activate macrophage immune cells and NK-Cells, plus in turn, the T-Cells, and B-Cells including selected cytokines and complement. 

Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Grant WB, Mohr SB. Ann Epidemiol. 2009 Jul;19(7):446-54. Epub 2009 Mar 9. PMID: 19269856 CONCLUSION: These findings provide strong evidence that vitamin D status plays an important role in controlling the outcome of cancer. Support for the UVB-vitamin D-cancer theory is now scientifically strong enough to warrant use of vitamin D in cancer prevention, and as a component of treatment. More research studies would help to explore whether there are benefits beyond the substantial effects that have been observed.